709 related articles for article (PubMed ID: 31619203)
1. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
2. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.
Semrau S; Agaimy A; Pavel M; Lubgan D; Schmidt D; Cavallaro A; Golcher H; Grützmann R; Fietkau R
J Med Case Rep; 2019 Mar; 13(1):82. PubMed ID: 30902067
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of chemotherapy with cisplatin and 5-fluorouracil for recurrent small cell neuroendocrine carcinoma of the rectum: report of a case.
Okuyama T; Korenaga D; Tamura S; Yao T; Maekawa S; Watanabe A; Ikeda T; Sugimachi K
Surg Today; 1999; 29(2):165-9. PubMed ID: 10030743
[TBL] [Abstract][Full Text] [Related]
4. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
5. Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case.
Kuratate S; Inoue S; Chikakiyo M; Kaneda Y; Harino Y; Hirose T; Yagi T; Saitoh S; Sumitomo M; Fujino R; Satake N
J Med Invest; 2010 Aug; 57(3-4):338-44. PubMed ID: 20847536
[TBL] [Abstract][Full Text] [Related]
6. [Long-Term Survival of a Patient with Rectal Neuroendocrine Carcinoma after Treatment with Curative Resection and Adjuvant Chemotherapy with Capecitabine].
Furumoto K; Kogire M; Iizuka N
Gan To Kagaku Ryoho; 2015 Dec; 42(13):2485-8. PubMed ID: 26809310
[TBL] [Abstract][Full Text] [Related]
7. Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease.
Bruera G; Ricevuto E
Front Oncol; 2020; 10():172. PubMed ID: 32154172
[No Abstract] [Full Text] [Related]
8. [Two Cases of Neuroendocrine Carcinoma of Colon and Rectum].
Morimoto K; Kuwabara H; Ryu K; Sato T; Sanada T; Nakamura N; Goseki N
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2189-2191. PubMed ID: 33468903
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic primary rectal neuroendocrine carcinoma presented as a large pelvic mass.
Pittayanon R; Pantongrag-Brown L; Wisedopas N; Rerknimitr R
BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24493107
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Alifieris CE; Griniatsos J; Delis SG; Nikolaou M; Avgoustou C; Panagiotidis MI; Souferi-Chronopoulou E; Trafalis DT
Am J Clin Oncol; 2020 May; 43(5):305-310. PubMed ID: 32343515
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Rectal Neuroendocrine Carcinoma with Iris Metastasis].
Matsuo Y; Ichikawa Y; Sawada G; Takada A; Kim HM; Murakami M; Fukunaga H; Shirai S; Kondou S; Kimura H; Morita S
Gan To Kagaku Ryoho; 2023 May; 50(5):647-649. PubMed ID: 37218331
[TBL] [Abstract][Full Text] [Related]
12. A Rare Tumor Presenting as a Rectal Mass.
Kaila V; Lager D; Jain R
Gastroenterology; 2018 Aug; 155(2):273-275. PubMed ID: 29408635
[No Abstract] [Full Text] [Related]
13. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Kakuta S; Takayama W; Kou T; Satou M; Sugaya M
Gan To Kagaku Ryoho; 2016 Jan; 43(1):129-32. PubMed ID: 26809541
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
[TBL] [Abstract][Full Text] [Related]
17. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C
J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273
[TBL] [Abstract][Full Text] [Related]
18. A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.
Ochiai T; Komiyama S; Ikoma H; Kubota T; Nakanishi M; Ichikawa D; Kikuchi S; Fujiwara H; Sakakura C; Kokuba Y; Sonoyama T; Otsuji E
Int J Clin Oncol; 2010 Aug; 15(4):423-7. PubMed ID: 20221660
[TBL] [Abstract][Full Text] [Related]
19. Rectal Neuroendocrine Tumor with Synchronous Pancreatic Metastasis: A Case Report.
Masuoka Y; Furukawa D; Yazawa N; Izumi H; Yamada M; Mashiko T; Saito G; Okada K; Tanaka A; Suzuki T; Sadahiro S; Hirabayashi K; Nakagohri T
Tokai J Exp Clin Med; 2018 Jul; 43(2):38-44. PubMed ID: 29961930
[TBL] [Abstract][Full Text] [Related]
20. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
